As of 4:00pm ET
| -0.17 / -0.82%|
The 13 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 22.00, with a high estimate of 42.00 and a low estimate of 18.00. The median estimate represents a +7.11% increase from the last price of 20.54.
The current consensus among 18 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since August, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.